Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

被引:12
|
作者
Sugiura, Ayumi [1 ]
Joshita, Satoru [1 ]
Yamashita, Yuki [1 ]
Yamazaki, Tomoo [1 ]
Fujimori, Naoyuki [1 ]
Kimura, Takefumi [1 ]
Matsumoto, Akihiro [1 ,2 ]
Wada, Shuichi [3 ]
Mori, Hiromitsu [3 ]
Shibata, Soichiro [3 ]
Yoshizawa, Kaname [4 ]
Morita, Susumu [4 ]
Furuta, Kiyoshi [5 ]
Kamijo, Atsushi [5 ]
Iijima, Akihiro [6 ]
Kako, Satoko [6 ]
Maruyama, Atsushi [7 ]
Kobayashi, Masakazu [8 ]
Komatsu, Michiharu [8 ]
Matsumura, Makiko [9 ]
Miyabayashi, Chiharu [10 ]
Ichijo, Tetsuya [11 ]
Takeuchi, Aki [12 ]
Koike, Yuriko [13 ]
Gibo, Yukio [14 ]
Tsukadaira, Toshihisa [15 ]
Inada, Hiroyuki [16 ]
Nakano, Yoshiyuki [17 ]
Usuda, Seiichi [18 ]
Kiyosawa, Kendo [18 ]
Tanaka, Eiji [19 ]
Umemura, Takeji [1 ,20 ]
机构
[1] Shinshu Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[2] Shinshu Univ Hosp, Consultat Ctr Hepat Dis, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[3] Japanese Red Cross Soc Nagano Hosp, Dept Gastroenterol, 22-1 Wakasato, Nagano, Nagano 3800928, Japan
[4] Natl Hosp Org, Shinshu Ueda Med Ctr, Dept Gastroenterol, 27-21 Midorigaoka, Ueda, Nagano 3868610, Japan
[5] Natl Hosp Org, Matsumoto Med Ctr, Dept Gastroenterol, 20-30 Muraimachiminami, Matsumoto, Nagano 3998701, Japan
[6] Nagano Prefectural Kiso Hosp, Dept Internal Med, 6613-4 Fukushima, Kiso, Nagano 3978555, Japan
[7] Ina Cent Hosp, Dept Gastroenterol, 1313-1 Koshiroukubo, Ina, Nagano 3968555, Japan
[8] Japanese Red Cross Soc Suwa Hosp, Dept Gastroenterol, 5-11-50 Kogandori, Suwa, Nagano 3928510, Japan
[9] Nagano Chuo Hosp, Dept Gastroenterol, 1570 Tsuruga Nishitsurugamachi, Nagano, Nagano 3800814, Japan
[10] Chikuma Cent Hosp, Dept Gastroenterol, 58 Kuiseshita, Chikuma, Nagano 3870011, Japan
[11] Japanese Red Cross Soc Azumino Hosp, Dept Gastroenterol, 5685 Toyoshina, Azumino, Nagano 3998205, Japan
[12] Aki Naika Clin, 236-1 Nozawa, Saku, Nagano 3850053, Japan
[13] Kawanakajima Clin, 1942-25 Kawanagajima Machi, Nagano, Nagano 3812221, Japan
[14] Gibo Hepatol Clin, 1-34-20 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[15] Kenwakai Hosp, Dept Gastroenterol, 1936 Kanaenakadaira, Iida, Nagano 3958522, Japan
[16] Kanebako Internal Med Clin, 320-2 Kanebako, Nagano, Nagano 3810007, Japan
[17] Nakano Gastroenterol Clin, 4-13-5 Muraimachiminami, Matsumoto, Nagano 3990036, Japan
[18] Aizawa Hosp, Gastroenterol Ctr, 2-5-1 Honjo, Matsumoto, Nagano 3900814, Japan
[19] Shinshu Univ, Dept Community Med Promot, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
[20] Shinshu Univ, Inst Biomed Sci, Dept Life Innovat, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan
基金
日本学术振兴会;
关键词
chronic hepatitis C; hepatitis C virus; glecaprevir; pibrentasvir; retreatment; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; LIVER-BIOPSY; GENOTYPE; HCV; FIBROSIS;
D O I
10.3390/biomedicines8040074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HCV patients (n = 182) were compared for clinical features and outcomes between first treatment (n = 159) and retreatment (n = 23) G/P groups. Overall, 77 patients (42.3%) were male, the median age was 68 years, and 86/66/1/4 cases had genotype 1/2/1 + 2/3, respectively. An SVR was achieved in 97.8% (178/182) of cases by intention-to-treat analysis and 99.4% (178/179) of cases by per-protocol analysis. There were no remarkable differences between the first treatment and retreatment groups for male (42.8% vs. 39.1%, p = 0.70), median age (68 vs. 68 years, p = 0.36), prior hepatocellular carcinoma (5.8% vs. 8.7%, p = 0.59), or the fibrosis markers AST-to-platelet ratio index (APRI) (0.5 vs. 0.5, p = 0.80) and fibrosis-4 (FIB-4) index (2.2 vs. 2.6, p = 0.59). The retreatment group had a significantly more frequent history of interferon treatment (12.3% vs. 52.2%, p < 0.01) and the Y93H mutation (25.0% vs. 64.7%, p = 0.02). The number of retreatment patients who had experienced 3, 2, and 1 DAA treatment failures was 1, 3, and 19, respectively, all of whom ultimately achieved an SVR by G/P treatment. In conclusion, G/P was effective and safe for both HCV first treatment and retreatment cases despite the retreatment group having specific resistance mutations for other prior DAAs. As G/P treatment failure has been reported for P32 deletions, clinicians should consider resistance mutations during DAA selection.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
    D'Ambrosio, Roberta
    Pasulo, Luisa
    Puoti, Massimo
    Vinci, Maria
    Schiavini, Monica
    Lazzaroni, Sergio
    Soria, Alessandro
    Gatti, Federico
    Menzaghi, Barbara
    Aghemo, Alessio
    Capelli, Francesca
    Rumi, Maria Grazia
    Morini, Lorenzo
    Giorgini, Alessia
    Pigozzi, Marie Graciella
    Rossini, Angelo
    Maggiolo, Franco
    Pan, Angelo
    Memoli, Massimo
    Spinelli, Ombretta
    Del Poggio, Paolo
    Saladino, Valeria
    Spinetti, Angiola
    De Bona, Anna
    Capretti, Andrea
    Uberti-Foppa, Caterina
    Bonfanti, Paolo
    Terreni, Natalia
    Menozzi, Fernanda
    Colombo, Alberto Eraldo
    Giglio, Omar
    Centenaro, Riccardo
    Borghi, Marta
    Baiguera, Chiara
    Picciotto, Viviana
    Landonio, Simona
    Gori, Andrea
    Magnani, Carlo
    Noventa, Franco
    Paolucci, Stefania
    Lampertico, Pietro
    Fagiuoli, Stefano
    JOURNAL OF HEPATOLOGY, 2019, 70 (03) : 379 - 387
  • [2] Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
    Hsu, Shih-Jer
    Chiu, Min-Chin
    Fang, Yu-Jen
    Yang, Tsung-Hua
    Yu, Jian-Jyun
    Chen, Chieh-Chang
    Kuo, Chia-Chi
    Lee, Ji-Yuh
    Chen, Chien-Hung
    Chen, Ding-Shinn
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2019, 118 (08) : 1187 - 1192
  • [3] Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir for genotype 6 chronic hepatitis C
    Chen, Jyh-Jou
    Chiu, Yen-Cheng
    Lee, Pei-Lun
    Tung, Hung-Da
    Chiu, Hung-Chih
    Chien, Shih-Chieh
    Cheng, Pin-Nan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2265 - 2272
  • [4] Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
    Liu, Chen-Hua
    Liu, Chun-Jen
    Hung, Chien-Ching
    Hsieh, Szu-Min
    Su, Tung-Hung
    Sun, Hsin-Yun
    Tseng, Tai-Chung
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    LIVER INTERNATIONAL, 2020, 40 (04) : 758 - 768
  • [5] Real-World Safety and Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir and Glecaprevir/Pibrentasvir in Hepatitis C Infected Patients
    Saxena, Varun
    Chamberland, Scott
    Hurley, Leo
    Lai, Jennifer B.
    Truong, Elizabeth
    Marcus, Julia
    Champsi, Jamila
    Hare, Brad B.
    Korn, Daniel
    Ready, Joanna B.
    Seo, Suk
    Witt, David J.
    Silverberg, Michael J.
    HEPATOLOGY, 2018, 68 : 418A - 419A
  • [6] Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
    Lu, Mei
    Rupp, Loralee B.
    Melkonian, Christina
    Trudeau, Sheri
    Daida, Yihe G.
    Schmidt, Mark A.
    Gordon, Stuart C.
    ADVANCES IN THERAPY, 2024, 41 (02) : 744 - 758
  • [7] Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis
    Mei Lu
    Loralee B. Rupp
    Christina Melkonian
    Sheri Trudeau
    Yihe G. Daida
    Mark A. Schmidt
    Stuart C. Gordon
    Advances in Therapy, 2024, 41 : 744 - 758
  • [8] Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland
    Mullhaupt, Beat
    Semela, David
    Ruckstuhl, Lisa
    Magenta, Lorenzo
    Clerc, Olivier
    Torgler, Ralph
    Negro, Francesco
    Semmo, Nasser
    SWISS MEDICAL WEEKLY, 2021, 151
  • [9] Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal
    Vera, Jose
    Gomes, Andre
    Povoas, Diana
    Seixas, Diana
    Maltez, Fernando
    Pedroto, Isabel
    Maia, Luis
    Mota, Margarida
    Vieira, Maria Joao
    Manata, Maria Jose
    Ferreira, Paula
    Lino, Sara
    Guedes, Tiago P. E. R. E. I. R. A.
    Marques, Nuno
    ACTA MEDICA PORTUGUESA, 2024, 37 (05) : 323 - 333
  • [10] Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
    Forns, Xavier
    Feld, Jordan J.
    Dylla, Douglas E.
    Pol, Stanislas
    Chayama, Kazuaki
    Hou, Jinlin
    Heo, Jeong
    Lampertico, Pietro
    Brown, Ashley
    Bondin, Mark
    Tatsch, Fernando
    Burroughs, Margaret
    Marcinak, John
    Zhang, Zhenzhen
    Emmett, Amanda
    Gordon, Stuart C.
    Jacobson, Ira M.
    ADVANCES IN THERAPY, 2021, 38 (06) : 3409 - 3426